---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-008420"
form_type: "8-K"
ticker: "HSCS"
cik: "0001468492"
company_name: "HeartSciences Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:33:51.824612+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# HeartSciences reports no FQ3 2026 revenue, cash at $3.4M; MyoVista platform advances

## Summary
- No revenue for FQ3 2026; cash and equivalents $3.4M, shareholders' equity $2.7M as of Jan 31.
- MyoVista Insights platform got major upgrade March 13; deploying across health systems.
- MyoVista wavECG device submitted to FDA for 510(k) clearance in Dec 2025.
- Company expects key customer wins and initial revenues during 2026.
- Management to host investor call after ACC meeting to demo platform.

## SEC filing metadata
- accession: 0001437749-26-008420
- form_type: 8-K
- ticker: HSCS
- cik: 0001468492
- company_name: HeartSciences Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468492/000143774926008420/0001437749-26-008420-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468492/000143774926008420/hscs20251229_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-008420
- JSON: https://secwatch.observer/filing/0001437749-26-008420.json
- Plain text: https://secwatch.observer/filing/0001437749-26-008420.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.